Meeting Coverage:

American Academy of Ophthalmology

AAO: 2024

A Look at Topline Data: EYP-1901

Show Description +

Dr. Regillo summarizes findings from the phase 2 DAVIO2 study of EYP-1901 (EyePoint Pharmaceuticals) for the treatment of wet AMD, sharing 12-month end-of-study data.

Posted: 10/28/2024

Up Next

Updates on a Novel Oral Therapy for DME

Joel A. Pearlman, MD, PhD


The Promise of a Wnt Agonist

Charles C. Wykoff, MD, PhD

The Risk of PVR Revealed

Mathew W. MacCumber, MD, PHD

The 2024 Charles L Schepens MD Lecture

Steve Charles, MD, FACS, FICS

Fellow-Eye Dosing of ABBV-RGX-314 Gene Therapy

Arshad M. Khanani, MD, MA, FASRS

Glaucoma Lasers: What’s New?

Sarah Van Tassel, MD

Visual Field Progression in the LiGHT Trial

Gus Gazzard, MA(Cantab), MD, MBBChir, FRCOphth

A Look at Topline Data: EYP-1901

Dr. Regillo summarizes findings from the phase 2 DAVIO2 study of EYP-1901 (EyePoint Pharmaceuticals) for the treatment of wet AMD, sharing 12-month end-of-study data.

Posted: 10/28/2024


Please log in to leave a comment.

More From AAO: 2024 Coverage